Astellas To Pay $7M To End Mycamine FCA Suit

Law360, Washington (April 16, 2014, 4:30 PM EDT) -- Astellas Pharma US Inc. has agreed to pay $7.3 million to settle a whistleblower False Claims Act suit from a former sales representative alleging that it marketed antifungal treatment Mycamine off-label for pediatric use and that as a result, Medicaid paid for unlawful prescriptions of the drug, the U.S. Department of Justice announced Wednesday.

The deal resolves allegations that between 2005 and 2010, Astellas — the U.S. unit of a Japanese drugmaker — knowingly promoted Mycamine for pediatric use, without approval from the U.S. Food and...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.